Aktie A244460 OLIPASS CORPORATION
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen OLIPASS Corporation

Aktien

A244460

KR7244460002

A244460

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 07.06.2024 		% 5 Tage % 1. Jan.
481 KRW +2,12 % Intraday Chart für OLIPASS Corporation -0,21 % -37,86 %
2023 OliPass Corporation veröffentlicht schmerzhafte, aber lustige klinische Ergebnisse einer Phase 2a-Studie mit dem selektiven Nav1.7-Inhibitor OLP-1002 bei OA-Patienten CI
2023 OLIPASS Corporation meldet Ergebnis für das am 31. Dezember 2022 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
OLIPASS Corporation announced that it has received KRW 3.5 billion in funding
OLIPASS Corporation announced that it expects to receive KRW 5 billion in funding
OLIPASS Corporation announced that it expects to receive KRW 12.50000032 billion in funding
OliPass Corporation Discloses Painful But Hilarious Clinical Findings from a Phase 2a Trial in OA Patients with Nav1.7 Selective Inhibitor OLP-1002
OLIPASS Corporation announced that it has received KRW 4.99998978 billion in funding
OLIPASS Corporation announced that it expects to receive KRW 4.999998885 billion in funding
OLIPASS Corporation announced that it expects to receive KRW 4.99998978 billion in funding
OLIPASS Corporation(KOSDAQ:A244460) dropped from S&P Global BMI Index
OLIPASS Corporation Reports Earnings Results for the Full Year Ended December 31, 2022
OliPass Corporation Announces Nav1.7 Selective Inhibitor OLP-1002 Shows Strong Efficacy and Long Therapeutic Duration According to Interim Findings from Phase 2A Study in OA Patients
OLIPASS Corporation announced that it expects to receive KRW 2.999989475 billion in funding from BNB Asset Co., Ltd.
Vanda Pharmaceuticals Inc. and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics
OliPass Corporation Moves Forward to Second Stage of Phase 2a Trial for Pain Killer OLP-1002
OliPass Corporation Announces Commencement of Dosing in Phase 2a Trial for Pain Killer OLP-1002
OLIPASS Corporation Announces SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
OLIPASS Corporation announced that it has received KRW 35.4996288 billion in funding from a group of investors
OLIPASS Corporation announced that it expects to receive KRW 35.4996288 billion in funding from a group of investors
OLIPASS Corporation(KOSDAQ:A244460) added to S&P Global BMI Index
OLIPASS Corporation announced that it has received KRW 14 billion in funding from KB Securities Co.,Ltd, Daishin Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.
OLIPASS Corporation announced that it expects to receive KRW 14 billion in funding from KB Securities Co.,Ltd, Daishin Securities Co., Ltd., Mirae Asset Daewoo Co., Ltd., NH Investment & Securities Co., Ltd.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A244460 Aktie
  4. Nachrichten OLIPASS Corporation
  5. Andere Sprachen
-40 % Zeitlich begrenztes Angebot: Unsere Abonnements führen Sie zu den besten Investitionen von morgen.
PROFITIEREN SIE JETZT